Compare NMTC & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NMTC | GBIO |
|---|---|---|
| Founded | 2009 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.5M | 36.3M |
| IPO Year | N/A | 2020 |
| Metric | NMTC | GBIO |
|---|---|---|
| Price | $0.79 | $5.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $2.23 | ★ $8.88 |
| AVG Volume (30 Days) | ★ 252.9K | 61.5K |
| Earning Date | 12-17-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $12,097,692.00 | ★ $15,270,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $31.19 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 250.35 | N/A |
| 52 Week Low | $0.40 | $3.00 |
| 52 Week High | $1.39 | $12.50 |
| Indicator | NMTC | GBIO |
|---|---|---|
| Relative Strength Index (RSI) | 62.85 | 53.96 |
| Support Level | $0.65 | $5.20 |
| Resistance Level | $0.83 | $5.54 |
| Average True Range (ATR) | 0.07 | 0.24 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 92.18 | 66.67 |
NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.